Social media posts about glucagon-like peptide-1 receptor agonists may identify patient concerns not captured in clinical trials, according to a study published ...

Vabysmo is a bispecific antibody designed to inhibit vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2).

The ACHIEVE-4 trial evaluated the efficacy and safety of orforglipron in adults with type 2 diabetes and obesity or overweight with increased risk of cardiovascular events.

Federal health officials are considering Dr Erica Schwartz to lead the US Centers for Disease Control and Prevention (CDC), according to people familiar with th ...

Foundayo, an oral GLP-1, now available and with new trial data; Filspari and Sdamlo gain approval; and the FDA invites ...

The expanded labeling reinforces Caldolor’s role in multimodal analgesia, offering a non-opioid option for postoperative pain ...

Twelve recommendations issued, including suggestion for no anticoagulants for pediatric patients with solid cancer, trauma, critical illness.

The FDA is inviting manufacturers to submit sNDAs for treating decreased libido in men with idiopathic hypogonadism.

Following favorable phase 1 data showing significant reductions in HBV DNA and RNA, the FDA has fast tracked pevifoscorvir sodium for chronic HBV infection.

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

Nephrologists now have an approved treatment option for FSGS patients without nephrotic syndrome following the latest FDA ...